ZLAB vs ZYME

For growth investors, Zymeworks Inc.

(ZYME) is the stronger pick with 38. 9% revenue growth year-over-year, versus 15. 3% for Zai Lab Limited (ZLAB). Analysts rate Zai Lab Limited (ZLAB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Zymeworks Inc.

(ZYME) delivered a total return of -6. 4%, compared to -86. 5% for Zai Lab Limited (ZLAB). Over 10 years, the gap is even starker: ZYME returned +112. 4% versus ZLAB's -24. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zymeworks Inc.

(ZYME) is the lower-risk stock at 0. 97β versus Zai Lab Limited's 1. 21β — meaning ZLAB is approximately 25% more volatile than ZYME relative to the S&P 500. On balance sheet safety, Zymeworks Inc. (ZYME) carries a lower debt/equity ratio of 7% versus 31% for Zai Lab Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zymeworks Inc.

(ZYME) is pulling ahead at 38. 9% versus 15. 3% for Zai Lab Limited (ZLAB). On earnings-per-share growth, the picture is similar: Zai Lab Limited grew EPS 38. 5% year-over-year, compared to 33. 3% for Zymeworks Inc.. Over a 3-year CAGR, ZLAB leads at 28. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zai Lab Limited (ZLAB) is the more profitable company, earning -38.

1% net margin versus -76. 6% for Zymeworks Inc. — meaning it keeps -38. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZLAB leads at -49. 9% versus -87. 3% for ZYME. At the gross margin level — before operating expenses — ZYME leads at 89. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ZLAB: 66.

6% to $35. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Zymeworks Inc.

(ZYME) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97), +112. 4% 10Y return). Both have compounded well over 10 years (ZYME: +112. 4%, ZLAB: -24. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.